High-grade serous ovarian cancer (HGSC) is the most common subtype of ovarian cancer, with a poor prognosis; however, most studies concerning ovarian carcinoma have focused mainly on clear cell carcinoma. The involvement of hepatocyte nuclear factor 1β (HNF1B) in the carcinogenesis of HGSC has not yet been fully elucidated. To the best of our knowledge, the present study is the first to analyse the expression of the possible downstream target of HNF1B, enoyl-CoA (Δ) isomerase 2 (ECI2), in HGSC. The present study performed a comprehensive analysis of HNF1B mRNA and protein expression, and epigenetic and genetic changes, as well as an analysis of ECI2 mRNA and protein expression in 122 cases of HGSC. HNF1B protein expression was detected in 28/122 cases, and was positively associated with lymphovascular invasion (P=0.025). Protein expression of ECI2 was detected in 115/122 cases, but no associations with clinicopathological variables were revealed. Therefore, ECI2 does not seem to function as a suitable prognostic marker for HGSC. In the sample set, a positive correlation between HNF1B and ECI2 protein expression was detected (P=0.005). HNF1B mRNA was also positively correlated with HNF1B protein expression (P=0.001). HNF1B promoter methylation was detected in 26/67 (38.8%) of cases. A novel pathogenic somatic HNF1B mutation was detected in 1/61 (1.6%) of the analysed HGSC cases. No other correlations between the examined SNPs (rs4430796, rs757210 and rs7405776), HNF1B promoter methylation, HNF1B/ECI2 expression or clinicopathological characteristics were found.

Gynecologic Oncology Center Department of Obstetrics and Gynecology 1st Faculty of Medicine Charles University and General University Hospital Prague 12800 Prague Czech Republic

Institute of Biology and Medical Genetics 1st Faculty of Medicine Charles University and General University Hospital Prague 12800 Prague Czech Republic

Institute of Pathology 1st Faculty of Medicine Charles University and General University Hospital Prague 12800 Prague Czech Republic

Zobrazit více v PubMed

Liu Y, Kanyomse Q, Xie Y. Tumor-suppressive activity of Hnf1β in Wilms' tumor. Biosci Biotechnol Biochem. 2019;83:2008–2015. doi: 10.1080/09168451.2019.1611409. PubMed DOI

Suzuki E, Kajita S, Takahashi H, Matsumoto T, Tsuruta T, Saegusa M. Transcriptional upregulation of HNF-1β by NF-KB in ovarian clear cell carcinoma modulates susceptibility to apoptosis through alteration in bcl-2 expression. Lab Invest. 2015;95:962–972. doi: 10.1038/labinvest.2015.73. PubMed DOI

Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, Yasugi T, Taketani Y, Hirohashi S. Expression profiling in ovarian clear cell carcinoma: Identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol. 2003;163:2503–2512. doi: 10.1016/S0002-9440(10)63605-X. PubMed DOI PMC

Bartu M, Dundr P, Nemejcova K, Ticha I, Hojny H, Hajkova N. The role of HNF1B in tumorigenesis of solid tumours: A review of current knowledge. Folia Biol (Praha) 2018;64:71–83. PubMed

Ross-Adams H, Ball S, Lawrenson K, Halim S, Russell R, Wells C, Strand SH, Ørntoft TF, Larson M, Armasu S, et al. HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer. Oncotarget. 2016;7:74734–74746. doi: 10.18632/oncotarget.12543. PubMed DOI PMC

Matsui A, Fujimoto J, Ishikawa K, Ito E, Goshima N, Watanabe S, Semba K. Hepatocyte nuclear factor 1 beta induces transformation and epithelial-to-mesenchymal transition. FEBS Lett. 2016;590:1211–1221. doi: 10.1002/1873-3468.12147. PubMed DOI

Kato N, Sasou S, Motoyama T. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol. 2006;19:83–89. doi: 10.1038/modpathol.3800492. PubMed DOI

Mandato VD, Farnetti E, Torricelli F, Abrate M, Casali B, Ciarlini G, Pirillo D, Gelli MC, Nicoli D, Grassi M, et al. HNF1B polymorphism influences the prognosis of endometrial cancer patients: A cohort study. BMC Cancer. 2015;15:229. doi: 10.1186/s12885-015-1246-5. PubMed DOI PMC

Setiawan VW, Haessler J, Schumacher F, Cote ML, Deelman E, Fesinmeyer MD, Henderson BE, Jackson RD, Vöckler JS, Wilkens LR, et al. HNF1B and endometrial cancer risk: Results from the PAGE study. PLoS One. 2012;7:e30390. doi: 10.1371/journal.pone.0030390. PubMed DOI PMC

Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, et al. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun. 2013;4:1628. doi: 10.1038/ncomms2629. PubMed DOI PMC

Spurdle AB, Thompson DJ, Ahmed S, Ferguson K, Healey CS, O'Mara T, Walker LC, Montgomery SB, Dermitzakis ET, Australian National Endometrial Cancer Study Group et al. Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat Genet. 2011;43:451–454. doi: 10.1038/ng.812. PubMed DOI PMC

Kato N, Motoyama T. Hepatocyte nuclear factor-1beta (HNF-1beta) in human urogenital organs: Its expression and role in embryogenesis and tumorigenesis. Histol Histopathol. 2009;24:1479–1486. PubMed

Yamamoto S, Tsuda H, Aida S, Shimazaki H, Tamai S, Matsubara O. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum Pathol. 2007;38:1074–1080. doi: 10.1016/j.humpath.2006.12.018. PubMed DOI

Fadare O, Liang SX. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: Lack of specificity for endometrial clear cell carcinoma. Appl Immunohistochem Mol Morphol. 2012;20:580–587. doi: 10.1097/PAI.0b013e31824973d1. PubMed DOI

Kao YC, Lin MC, Lin WC, Jeng YM, Mao TL. Utility of hepatocyte nuclear factor-1β as a diagnostic marker in ovarian carcinomas with clear cells. Histopathology. 2012;61:760–768. doi: 10.1111/j.1365-2559.2012.04267.x. PubMed DOI

Nemejcova K, Ticha I, Kleiblova P, Bártů M, Cibula D, Jirsová K, Dundr P. Expression, epigenetic and genetic changes of HNF1B in endometrial lesions. Pathol Oncol Res. 2016;22:523–530. doi: 10.1007/s12253-015-0037-2. PubMed DOI

Dan C, Zhang H, Zeng W, Huang L, Gong X, Li H, Yang E, Wang L, Yao Q. HNF1B expression regulates ECI2 gene expression, potentially serving a role in prostate cancer progression. Oncol Lett. 2019;17:1094–1100. PubMed PMC

Houten SM, Violante S, Ventura FV, Wanders RJ. The biochemistry and physiology of mitochondrial fatty acid β-oxidation and its genetic disorders. Annu Rev Physiol. 2016;78:23–44. doi: 10.1146/annurev-physiol-021115-105045. PubMed DOI

Itkonen HM, Brown M, Urbanucci A, Tredwell G, Ho Lau C, Barfeld S, Hart C, Guldvik IJ, Takhar M, Heemers HV, et al. Lipid degradation promotes prostate cancer cell survival. Oncotarget. 2017;8:38264–38275. doi: 10.18632/oncotarget.16123. PubMed DOI PMC

Fan J, Li X, Issop L, Culty M, Papadopoulos V. ACBD2/ECI2-mediated peroxisome-mitochondria interactions in leydig cell steroid biosynthesis. Mol Endocrinol. 2016;30:763–782. doi: 10.1210/me.2016-1008. PubMed DOI PMC

Hirsch FR, Dziadziuszko R, Thatcher N, Mann H, Watkins C, Parums DV, Speake G, Holloway B, Bunn PA, Jr, Franklin WA. Epidermal growth factor receptor immunohistochemistry: Comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. Cancer. 2008;112:1114–1121. doi: 10.1002/cncr.23282. PubMed DOI PMC

Bartu M, Hojny J, Hajkova N, Michálková R, Krkavcová E, Simon K, Frýba V, Stružinská I, Němejcová K, Dundr P. Expression, epigenetic, and genetic changes of HNF1B in colorectal lesions: An analysis of 145 cases. Pathol Oncol Res. 2020;26:2337–2350. doi: 10.1007/s12253-020-00830-2. PubMed DOI

Dundr P, Bartu M, Hojny J, Michálková R, Hájková N, Stružinská I, Krkavcová E, Hadravský L, Kleissnerová L, Kopejsková J, et al. HNF1B, EZH2 and ECI2 in prostate carcinoma. Molecular, immunohistochemical and clinico-pathological study. Sci Rep. 2020;10:14365. doi: 10.1038/s41598-020-71427-7. PubMed DOI PMC

Kim HY. Statistical notes for clinical researchers: Chi-squared test and Fisher's exact test. Restor Dent Endod. 2017;42:152–155. doi: 10.5395/rde.2017.42.2.152. PubMed DOI PMC

Cancer Genome Atlas Research Network, corp-author. The molecular taxonomy of primary prostate cancer. Cell. 2015;163:1011–1025. doi: 10.1016/j.cell.2015.10.025. PubMed DOI PMC

Kato N, Tamura G, Motoyama T. Hypomethylation of hepatocyte nuclear factor-1beta (HNF-1beta) CpG island in clear cell carcinoma of the ovary. Virchows Arch. 2008;452:175–180. doi: 10.1007/s00428-007-0543-z. PubMed DOI

Lau HH, Ng NHJ, Loo LSW, Jasmen JB, Teo AKK. The molecular functions of hepatocyte nuclear factors-In and beyond the liver. J Hepatol. 2018;68:1033–1048. doi: 10.1016/j.jhep.2017.11.026. PubMed DOI

Kalloger SE, Kobel M, Leung S, Mehl E, Gao D, Marcon KM, Chow C, Clarke BA, Huntsman DG, Gilks CB. Calculator for ovarian carcinoma subtype prediction. Mod Pathol. 2011;24:512–521. doi: 10.1038/modpathol.2010.215. PubMed DOI

Tomassetti A, De Santis G, Castellano G, Miotti S, Mazzi M, Tomasoni D, Van Roy F, Carcangiu ML, Canevari S. Variant HNF1 modulates epithelial plasticity of normal and transformed ovary cells. Neoplasia. 2008;10:1481–1492. doi: 10.1593/neo.81004. PubMed DOI PMC

Bowtell DD, Bohm S, Ahmed AA, Aspuria PJ, Bast RC, Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, et al. Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15:668–679. doi: 10.1038/nrc4019. PubMed DOI PMC

Terasawa K, Toyota M, Sagae S, Ogi K, Suzuki H, Sonoda T, Akino K, Maruyama R, Nishikawa N, Imai K, et al. Epigenetic inactivation of TCF2 in ovarian cancer and various cancer cell lines. Br J Cancer. 2006;94:914–921. doi: 10.1038/sj.bjc.6602984. PubMed DOI PMC

Bubancova I, Kovarikova H, Laco J, Ruszova E, Dvorak O, Palicka V, Chmelarova M. Next-generation sequencing approach in methylation analysis of HNF1B and GATA4 genes: Searching for biomarkers in ovarian cancer. Int J Mol Sci. 2017;18:474. doi: 10.3390/ijms18020474. PubMed DOI PMC

Baranova I, Kovarikova H, Laco J, Sedlakova I, Vrbacky F, Kovarik D, Hejna P, Palicka V, Chmelarova M. Identification of a four-gene methylation biomarker panel in high-grade serous ovarian carcinoma. Clin Chem Lab Med. 2020;58:1332–1340. doi: 10.1515/cclm-2019-1319. PubMed DOI

Chaffer CL, San Juan BP, Lim E, Weinberg RA. EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 2016;35:645–654. doi: 10.1007/s10555-016-9648-7. PubMed DOI

Huang W, Cheng X, Ji J, Zhang J, Li Q. The application value of HNF-1β transcription factor in the diagnosis of ovarian clear cell carcinoma. Int J Gynecol Pathol. 2016;35:66–71. doi: 10.1097/PGP.0000000000000213. PubMed DOI

Kobel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, Ewanowich CA, Soslow RA, Gilks CB. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol. 2009;33:14–21. doi: 10.1097/PAS.0b013e3181788546. PubMed DOI

Li Q, Zeng X, Cheng X, Zhang J, Ji J, Wang J, Xiong K, Qi Q, Huang W. Diagnostic value of dual detection of hepatocyte nuclear factor 1 beta (HNF-1β) and napsin A for diagnosing ovarian clear cell carcinoma. Int J Clin Exp Pathol. 2015;8:8305–8310. PubMed PMC

The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance

Comprehensive quantitative analysis of alternative splicing variants reveals the HNF1B mRNA splicing pattern in various tumour and non-tumour tissues